On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 billion), missing the consensus of 71.89 billion Danish kroner. The global sales increased 21% year over year (up 23% at constant currency), driven by increased sales across the portfolio. GLP-1 diabetes sales increased by 15% at CER to 34.94 billion Danish kroner, and Obesity care sales increased by 55% at CER to 18.80 billion Danish kroner. Also Read: Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug Insulin sales increased by 10% at CER to 12.51 billio…